HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks

Expert Review of Vaccines

Volumn 9, Issue 7, 2010, Pages 697-701

  Haupt, Richard M ^a   Sattler, Carlos ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; LETTER; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SERODIAGNOSIS; SEROLOGY; SINGLE DRUG DOSE; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK; VACCINATION;

EID: 77954687071     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.56     Document Type: Letter

References (26)

1. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines 8(12), 1663-1679 (2009).
2. Harper DM. Gardasil needs a new consent form. Expert Rev. Vaccines 8(12), 1613-1614 (2009).
3. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
4. Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298, 743-753 (2007).
5. Olsson S-E, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccines 5(10), 696-704 (2009).
6. Harper DM. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr. Opin. Obstet. Gynecol. 21(6), 457-464 (2009).
7. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007).
8. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161-2170 (2007).
9. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369, 1861-1868 (2007).
10. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009).
11. Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102(5), 325-339 (2010).
12. Garland SM, Steben M, Sings HL et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 199(6), 805-814 (2009).
13. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet. Gynecol. 108(6), 1361-1368 (2006).
14. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet. Gynecol. 85(5 Pt 1), 709-715 (1995).
15. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 124(7), 1626-1636 (2009).
16. Dawson B, Trapp RG. Basic and Clinical Biostatistics. Mcgraw-Hill, NY, USA (2004).
17. Stanley M. Prospects for new human papillomavirus vaccines. Curr. Opin. Infect. Dis. 23(1), 70-75 (2010).
18. Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5(10), 705-719 (2009).
19. Block SL, Brown DR, Chatterjee A et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr. Infect. Dis. J. 29(2), 95-101 (2010).
20. Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet. Gynecol. 114(6), 1179-1188 (2009).
21. Dana A, Buchanan KM, Goss MA et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet. Gynecol. 114(6), 1170-1178 (2009).
22. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 27(52), 7270-7281 (2009).
23. Richard M Haupt and Carlos Sattler. Response to Diane Harper 'Current Prophylactic HPV vaccines and gynecologic premalignancies' http://journals.lww. com/co-obgyn/Documents/Gardasil%20Response%20 to%20the%20Opinion%20Paper%20 Authored%20by%20Diane%20 Harper%20SUBMITTED%20 16Dec2009.pdf (Accessed April 2010) 102 WHO. Weekly epidemiological record Releve epidemiologique hebdomadaire http://www.who.int/wer/2009/wer8415.pdf/(Accessed April 2010)
24. WHO. Human papillomavirus (HPV) vaccine background paper http://www.who.int/immunization/documents/HPVBGpaper05032009.pdf (Accessed June 2010)
25. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Human papillomavirus vaccine (GARDASIL) http://www.tga.gov.au/ alerts/medicines/gardasil. htm (Accessed April 2010)
26. CDC. Summary of HPV adverse event reports published in JAMA. CDC website (2009) www. http://cdc.gov/vaccinesafety/ vaers/HPV-JAMA.htm (Accessed April 2010)